Rocavorexant, a novel, selective orexin-1 receptor antagonist: Safety, tolerability and pharmacokinetics in healthy adults and individuals with opioid use disorder.
- DOI
- 10.1002/bcp.70865
- Published
- 2026 Nov 6
- Container
- British journal of clinical pharmacology
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/bcp.70865,
title = {Rocavorexant, a novel, selective orexin-1 receptor antagonist: Safety, tolerability and pharmacokinetics in healthy adults and individuals with opioid use disorder.},
author = {Kankam M and Al-Awam R and Shiwach R and Huhn AS and Young MA and Dobbins RL},
year = {2026},
journal = {British journal of clinical pharmacology},
doi = {10.1002/bcp.70865},
url = {https://doi.org/10.1002/bcp.70865}
}RIS
TY - JOUR TI - Rocavorexant, a novel, selective orexin-1 receptor antagonist: Safety, tolerability and pharmacokinetics in healthy adults and individuals with opioid use disorder. AU - Kankam M AU - Al-Awam R AU - Shiwach R AU - Huhn AS AU - Young MA AU - Dobbins RL PY - 2026 JO - British journal of clinical pharmacology DO - 10.1002/bcp.70865 UR - https://doi.org/10.1002/bcp.70865 ER -
APA
M, K., R, A., R, S., AS, H., MA, Y., & RL, D. (2026). Rocavorexant, a novel, selective orexin-1 receptor antagonist: Safety, tolerability and pharmacokinetics in healthy adults and individuals with opioid use disorder.. British journal of clinical pharmacology. https://doi.org/10.1002/bcp.70865
Source records
- pubmed · retrieved 2026-11-10T05:11:09.654Z
- europe-pmc · retrieved 2026-11-10T05:11:09.678Z